A phase 1, open-label, dose-escalation trial of oral TSR-011 in patients with advanced solid tumours and lymphomas

Real-world outcomes in patients with ALK-positive non-small cell lung cancer treated with crizotinib

(2018) K.L. Davis et al.   Current Oncology

Management of Resistance to First-Line Anaplastic Lymphoma Kinase Tyrosine Kinase Inhibitor Therapy

(2018) Solange Peters et al.   CURRENT TREATMENT OPTIONS IN ONCOLOGY

Targeting ALK: Precision Medicine Takes on Drug Resistance

(2017) Jessica J. Lin et al.   Cancer Discovery

Crizotinib resistance: implications for therapeutic strategies

(2016) I. Dagogo-Jack et al.   ANNALS OF ONCOLOGY

Molecular Mechanisms of Resistance to First- and Second-Generation ALK Inhibitors in ALK-Rearranged Lung Cancer

(2016) J. F. Gainor et al.   Cancer Discovery

ALK inhibitors in non-small cell lung cancer: the latest evidence and developments

(2015) Ivana Sullivan et al.   Therapeutic Advances in Medical Oncology

First-Line Crizotinib versus Chemotherapy in ALK-Positive Lung Cancer

(2014) Benjamin J. Solomon et al.   NEW ENGLAND JOURNAL OF MEDICINE

19p13.1 Is a Triple-Negative-Specific Breast Cancer Susceptibility Locus

(2012) K. N. Stevens et al.   CANCER RESEARCH

Therapeutic strategies to overcome crizotinib resistance in non-small cell lung cancers harboring the fusion oncogene EML4-ALK

(2011) R. Katayama et al.   PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA

The biology and treatment of EML4-ALK non-small cell lung cancer

(2010) Takaaki Sasaki et al.   EUROPEAN JOURNAL OF CANCER

A mouse model for EML4-ALK-positive lung cancer

(2008) M. Soda et al.   PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA